Brachytherapy
Volume 6, Issue 1 , Pages 44-48 , January 2007

Improvements in prostate brachytherapy dosimetry due to seed stranding

  • Kevin Lin

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, CA
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, UCLA, 200 UCLA Medical Plaza, Suite B265, Los Angeles, CA 90095, USA. Tel.: +1-310-825-9771/776-0249; fax: +1-310-794-9795.
    • ,
  • Steve P. Lee

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, CA
    • ,
  • Jennifer S. Cho

      Affiliations

    • Biomedical Physics Graduate Program, University of California, Los Angeles, CA
    • ,
  • Robert E. Reiter

      Affiliations

    • Department of Urology, University of California, Los Angeles, CA
    • ,
  • John J. DeMarco

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, CA
    • ,
  • Timothy D. Solberg

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, CA
    • Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE

Received 19 June 2006 ,Revised 20 August 2006 ,Accepted 29 August 2006.

References 

  1. American Cancer Society, Inc., Cancer facts and figures, 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf.
  2. Adolfsson J, Brehmer M, Naslund E, et al. Iodine-125 brachytherapy for clinically localized prostate cancer: A 5-year follow-up of outcome and complications. Eur Urol. 1994;26:207–211
  3. Sharkey J, Cantor A, Solc Z, et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep. 2002;3:250–257
  4. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 1996;14:449–453
  6. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: Thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol. 2001;54:739–747
  7. Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 1993;3:240–249
  8. Al-Qaisieh B, Carey B, Ash D, et al. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:397–399
  9. Nag S, Vivekanandam S, Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:667–670
  10. Davis BJ, Pfeifer EA, Wilson TM, et al. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol. 2000;164:1661
  11. Merrick GS, Butler WM, Wallner KE, et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol. 2006;175:1376–1380
  12. Merrick GS, Butler WM, Wallner KE, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:437–447
  13. Potters L, Huang D, Calugaru E, et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003;62:1073–1077
  14. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  15. Nath R, Roberts K, Ng M, et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys. 1998;25:2293–2307
  16. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  17. Lee WR, deGuzman AF, Tomlinson SK, et al. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol. 2002;65:123–127
  18. Fagundes HM, Keys RJ, Wojcik MF, et al. Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPID Strand: A dosimetric analysis. Brachytherapy. 2004;3:136–140
  19. Fuller DB, Koziol JA, Feng AC. Prostate brachytherapy seed migration and dosimetry: Analysis of stranded sources and other potential predictive factors. Brachytherapy. 2004;3:10–19
  20. Reed DR, Wallner KE, Mueller A, et al. Rapid Strand vs. loose (Iodine-125 seeds): A prospective randomized trial. Brachytherapy. 2005;4:113
  21. Kaplan ID, Meskell PM, Lieberfarb M, et al. A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: A randomized trial. Brachytherapy. 2004;3:7–9
  22. Crook J. The pros and cons of linked versus loose seeds. Radiother Oncol. 2003;69(Suppl. 1):S39
  23. McLaughlin P, Narayana V, Pan C, et al. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds. Int J Radiat Oncol Biol Phys. 2006;64:144–150
  24. Stock RG, Nelson NS, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  25. Papagikos MA, Deguzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy. 2005;4:252–258
  26. Stock RG, Stone NN, Kao J, et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: Implications for treatment optimization. Cancer. 2000;89:1829–1834
  27. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  28. Crook J. Commentary on “a comparison of the precision of seeds deposited as loose seeds vs. suture-embedded seeds: A randomized trial” and “prostate brachytherapy seed migration and dosimetry: Analysis of stranded sources and other potential predictive factors”: To strand or not to strand—Is this really the question?. Brachytherapy. 2004;3:20–21
  29. McNeely LK, Stone NN, Presser J, et al. Influence of prostate volume on dosimetry results in real-time 125I seed implantation. Int J Radiat Oncol Biol Phys. 2004;58:292–299
  30. Yu Y, Waterman FM, Suntharalingam N, et al. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. Int J Radiat Oncol Biol Phys. 1996;34:717–725
  31. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  32. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  33. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  34. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996

PII: S1538-4721(06)00254-6

doi: 10.1016/j.brachy.2006.08.010

Brachytherapy
Volume 6, Issue 1 , Pages 44-48 , January 2007

Article Tools

* Image Usage & Resolution